|
Mike is a Partner at NEA where he specializes in healthcare investments in the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mike was Senior Vice President, Therapeutics and General Manager, of the Renal Division at Genzyme Corporation. During his time at Genzyme, Mike has worked as Vice President of Business Development for the Therapeutics Division, Product Manager for Ceredase and was instrumental in the worldwide launch of Cerezyme, Genzyme's $1 Billion therapies for Gaucher Disease. He also spent two years with Genzyme's Diagnostic products and services division. Mike is a member of the Life Sciences Advisory Board for Silicon Valley Bank; currently serves on the board of Amicus Therapeutics, Intarcia, CellGate, Novacea, Hyperion and Macroflux; and is actively involved with a number of life science and pharmaceutical companies. | 